AS-OCT produces better results after long-term dark adaptation

Article

A study announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.

A paper published in the Journal of Glaucoma has announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.

Dr Dejiao Li et al., Optoelectronics Research Centre, University of Southampton, Hampshire, UK, split 110 participants into 2 groups a study group and a control group. In the study group there were 70 suspects of primary angle closure and in the control group there were 40 normal participants. AS-OCT was used to measure the anterior chamber angle configuration and pupil diameter at both 3 minutes and 1.5 hours of dark adaptation.

The study group presented a significantly higher mean number of closed angle segments at 3 minutes of dark adaptation compared to 1.5 hours of dark adaptation or light conditions.

Pupil diameter was linked to the number of closed angle segments at 3 minutes of dark adaptation. Final intraocular pressure demonstrated an improved correlation with angle configuration segments at 3 minutes compared to 1.5 hours.

Overall, the dark room test with AS-OCT at 3 minutes was positive in a significantly high number of patients compared to dark room adaptation at 1.5 hours. The treatment was heavily advised as a method to identify glaucoma suspects.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.